Arcion Therapeutics’ Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
-Clinical Data Presented at American Pain Society Annual Meeting-
According to the abstract, patients receiving 0.1% clonidine gel reported significantly greater reductions in pain when compared to placebo (p=0.015). This improvement was demonstrated in the first week of the study (p=0.003). Participants in the 0.2% group did not differ from those in the placebo group, though a trend was observed (p=0.054). The 0.2% results may have been due to the fact that this group received 23% less gel in order to avoid higher systemic dosing. Consistent with this, clonidine blood levels in the 0.2% group were the same as that in the 0.1% group. Responder analysis revealed that 47.2% of patients across both treatment groups combined had 30% or more pain relief compared to 29.3% in the placebo group (p=0.031). Blood levels of clonidine varied from non-detectable to levels several-fold below the threshold required to treat hypertension (the original indication for clonidine). Patients with detectable clonidine in the blood experienced significantly greater pain reduction than patients in whom clonidine was not detected (p<0.05).
“These data demonstrate that ARC-4558 may offer a new approach to treating the pain associated with diabetic neuropathy. By applying the drug topically to the area of pain, systemic exposure is minimized, and hence, systemic side effects appear to be minimal. Moreover, this approach may be complementary to systemic approaches. We are now in the midst of an additional randomized, controlled Phase 2b trial to confirm the safety and efficacy of topical clonidine,” said
Previously published research has shown that in neuropathic pain conditions such as PDN, the signal that triggers pain actually arises at the level of the skin. The data reported today for ARC-4558 provide further rationale for applying therapies topically at the site of the pain. From a treatment standpoint, this approach has the potential to offer multiple benefits over orally bioavailable or patch-based treatments including more convenient application, uniform coverage of the affected site, lower systemic side-effects and fewer drug interactions.
The abstract, titled, “Topical clonidine gel (ARC-4558) reduces pain caused by diabetic neuropathy: Results of a multicenter, placebo-controlled clinical trial,” was authored by
About the Trial
The double-blind, placebo-controlled trial included 166 patients with chronic, bilateral, lower extremity, painful diabetic neuropathy. Patients were randomized to receive 0.1% or 0.2% topical clonidine gel or placebo gel, and remained on their existing pain management treatments. The gel was applied to both feet twice daily for the first two weeks and three times a day for six weeks. Participants rated their pain throughout the study.
About Painful Diabetic Neuropathy (PDN)
Diabetic neuropathy is one of the most common complications of diabetes mellitus that is associated with a number of painful conditions. According to 2008 estimates by the Centers for Disease Control and Prevention, nearly 24 million people in
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion’s product pipeline comprises multiple candidates to treat neuropathic pain.
SOURCE Arcion Therapeutics, Inc.